Thursday, November 3, 2011

zombie cells study may lead to antiaging drugs

research aging
Healt tips for the aging and how to controll over aging by the drugs prepared by the zombie cells. It's not quite the fountain of youth, but Mayo Clinic scientists may have hit upon a way to slow the aging process. The key, they report in a tantalizing new study, is purging the body of senescent cells - old "zombie" cells that no longer work as they should. "By attacking these cells and what they produce, one day we may be able to break the link between aging mechanisms and predisposition to diseases like heart disease, stroke, cancers and dementia," the clinic's Dr. James Kirkland, a co-author of the study, said in a written statement. "There is potential for a fundamental change in the way we provide treatment for chronic diseases in older people."

And maybe not just chronic diseases. The researchers say that eliminating senescent cells could also delay the onset of cataracts and the gradual loss of muscle tissue that often comes with aging.

How about slowing the progression of aging-related problems that have already shown up? The purging process may be able to do that too.

"Therapeutic interventions to get rid of senescent cells or block their effects may represent an avenue to make us feel more vital, healthier, and allow us to stay independent for a much longer time," the Mayo Clinic's Dr. Jan van Deursen, a study co-author, said in the statement.
antiaging drugs

The research - published in the journal Nature - grew out of the long-ago discovery that cells in the body don't keep dividing forever. Instead, they reach a state of limbo scientists call cellular senescence, in which they no longer divide but release substances that damage adjacent cells and cause inflammation. The immune system is supposed to sweep away these zombie cells but gradually loses its ability to do so.

But where nature has failed, science seems to have found a way.

The scientists started by genetically engineering mice to have a specific molecule in their senescent cells. Then they exposed these transgenic mice to a drug that stimulated the molecule, causing it to drill holes in the cells' outer membranes. Result? The cells self-destructed.
anti wrinkle
What happened to the mice? Those that were given the drug over the long term were slower to develop cataracts and other aging-relating health problems, Time reported.
"Mice that should have looked prematurely aged were essentially normal," Dr. Gary Kennedy, an expert on aging at Montefiore Medical Center in New York City, told USA Today.
anti aging product
If future studies confirm the findings, the hope is that it may be possible to develop drugs that would kill senescent cells in humans - or to find ways to rev up a flagging immune system's ability to sweep away the cells, the New York Times reported. Another possibility might be to find ways to destroy the inflammatory substances the cells produce, according to Time.

"I am very excited by the results," Dr. Norman E. Sharpless, University of North Carolina expert on aging, told the Times. "It suggests therapies that might work in real patients." Scientists may have found a way to put off some conditions of aging, according to a study in which they postponed or even prevented such afflictions as cataracts and wrinkle-inducing fat loss in mice by removing cells that had stopped dividing.

Most young, healthy cells divide continuously in order to keep body tissues and organs functioning properly, but eventually stop splitting—a state called senescence—and are replaced by others. Senescence occurs throughout life, but people's ability to clear such cells from their bodies decreases with age, leading to a buildup.

Loneliness linked to restlessness and disruptive sleep

Loneliness Linked To Disrupted Sleep A blank wall of social and professional antagonism faces the woman physician that forms a situation of singular and painful loneliness, leaving her without support, respect or professional counsel. Loneliness is significantly associated with sleep fragmentation, but not sleep duration or subjective sleep measures. Lianne M. Kurina, Ph.D., from the University of Chicago, and colleagues investigated whether loneliness was associated with sleep fragmentation or sleep duration. A total of 95 individuals from a communal society, with a mean age of 39.8 years, were interviewed about loneliness, depression, anxiety, and stress; and subjective sleep measures (sleep quality and daytime sleepiness) were assessed. Objective sleep properties, including sleep fragmentation and sleep duration, were measured using a wrist actigraph worn by the participants for one week.

The investigators found that, after controlling for age, gender, body mass index, risk of sleep apnea, and negative affect (comprising symptoms of depression and anxiety, and perceived stress), higher loneliness scores correlated with significantly higher levels of sleep fragmentation. There was no association of loneliness with sleep duration, or with either subjective sleep measure. A new US study reports this week that loneliness is linked to sleep disruption: people who scored themselves high on loneliness were also the ones whose monitored sleep patterns were most fragmented. Reporting their findings in the 1 November issue of the journal Sleep, lead author Dr Lianne Kurina, of the Department of Health Studies at the University of Chicago, and colleagues found however, that loneliness does not appear to be linked to duration of sleep.
In a press release from the American Academy of Sleep Medicine, Kurina said that:

"The relationship between loneliness and restless sleep appears to operate across the range of perceived connectedness."

"Our study provides evidence that those individuals who perceive themselves as less connected to others have more fragmented sleep. Sleep could be a pathway through which perceived social isolation influences health," the authors write. Loneliness is about perceived social isolation, feeling like an outcast, and reflects the difference between what a person wants and what they actually have in their social connections with others.
"Whether you're a young student at a major university or an older adult living in a rural community, we may all be dependent on feeling secure in our social environment in order to sleep soundly," said Kurina, adding that the findings of studies like these help us further understand how social and psychological factors impact our health.

While these conclusions seem plausible we should however, remind ourselves that this was a cross-sectional study and thus at the most can only assert whether links are strong or not: it cannot establish the direction of cause and effect.
Loneliness Linked To Disrupted Sleep
For example, an equally scientific explanation from these results could be as follows: disrupted sleep affects mood in a way that makes people less likely to engage with others to the level that they would like. This may seem less plausible, but the study is not of a design that can rule this out.

cystic fibrosis ‎ and drug relation

cystic fibrosis symptoms
is the first to halt the underlying processes that cause the inherited disease, which causes thick, sticky mucus to build up in the lungs and the pancreas and can lead to life-threatening infections, experts said.

"It has a huge significance for the whole cystic fibrosis community," said study author Dr. Bonnie Ramsey, director of the Center for Clinical and Translational Research at Seattle Children's Hospital and a professor at the University of Washington School of Medicine. "It's the first time we have developed a therapy directed at the abnormal proteins and showing that it can be corrected."

Only 4 percent to 5 percent of cystic fibrosis patients have the particular genetic variant that the drug is being studied to treat, but for them, the results could mean a significant improvement in their health, said Robert Beall, president and CEO of the Cystic Fibrosis Foundation.

"We're talking about adding decades to these people's lives, that's how profound this drug is," Beall said.

But Beall and other experts say the drug may end up helping people with other cystic fibrosis genetic variants, including the most common one, D508, one copy of which is present in more than 90 percent of people with cystic fibrosis.

Though ivacaftor (previously known as VX-770) on its own didn't work all that well in these patients, a trial looking at using ivacaftor in conjunction with another drug is currently under way. Results of that trial are expected in the fall of 2012, said Beall, whose organization has provided funding for VX-770 research.

In the study reported in the Nov. 3 issue of the New England Journal of Medicine, 161 patients aged 12 and older were randomly divided into two groups. One received the drug every 12 hours and the other received a placebo. All patients had at least one copy of the G551D mutation.

Researchers could tell the drug was working two weeks after people started taking it and the concentration of chloride in their sweat dropped, for some to levels seen in people without the disease. Very salty sweat is a telltale sign of the disease.

Patients also showed improved lung function, as measured by FEV1, or how much air they could blow out in one second.

"It's not surprising you would see an effect in two weeks. By changing the hydration of the mucus, you can clear it out better and open up the airways," Ramsey said. "We saw the improvement across all illness severities … That was very encouraging. We had been very worried once you had the lung damage or the infections you wouldn't be able to reverse it. That's not saying the lungs would return to normal, but there was more reversibility than we thought there would be."

Patients also experienced an average relative change in their lung function of 17 percent. Relative change means relative to where they started. The absolute change was about a 10 percent improvement.

At 48 weeks, patients on the drug were 55 percent less likely to have experienced an exacerbation, or an infection that left them ill and unable to work or hospitalized.

Patients on the drug also gained an average of 7 pounds, a huge feat for someone with cystic fibrosis, experts said. The weight gain brought people who were nutritionally deficient and underweight closer to a normal body weight, Ramsey said.

The results stayed consistent through 48 weeks, and there were few side effects, according to the study.

Best of all, patients reported feeling better, Beall said. "We had a lot of people call us and say it was incredible how much better they feel."

Cystic fibrosis is a progressive, inherited disease caused by a defect in the CF gene, which produces the CFTR (cystic fibrosis transmembrane conductance regulator) protein, which is important in the transport of salt and fluids in the cells of the lungs and digestive tract.

In healthy cells, when chloride moves out of cells, water follows, keeping the mucus around the cell hydrated.

In people with the faulty CFTR protein, the chloride channels don't work properly. Chloride and water in the cells of the lungs stay trapped inside the cell, causing the mucus to become thick, sticky and dehydrated.

Overtime, the abnormal mucus builds up in the lungs and in the pancreas, which helps to break down and absorb food. Patients with cystic fibrosis have both breathing problems and problems with maintaining weight.

In the lungs, the accumulation of the mucus leaves people prone to serious, hard-to-treat and recurrent infections. Overtime, the repeated infections destroy the lungs.

Though improving with inhaled antibiotics and other treatments, the average life expectancy for a person with cystic fibrosis is about 39, according to the Cystic Fibrosis Foundation.

Ivacaftor is believed to work by opening up the chloride channels, allowing the water to exit the cell and the mucus to become better hydrated. For people with the more common variant, D508, ivacaftor will likely open the channels, but only if the protein is properly transported to the surface of the cell. That's where a second drug would come in, experts explained.

Vertex Pharmaceuticals, the company developing the drug, has applied for expedited U.S. Food and Drug Administration approval. If the FDA grants the company's request, that would shorten the review time to six months from the usual 10, and would mean the FDA would make a decision by April, according to Dawn Kalmar, director of product communications for Vertex.

The drug will be marketed under the brand name Kalydeco.

Dr. Pamela Davis, dean of Case Western Reserve University School of Medicine, in Cleveland, said the drug holds great promise for cystic fibrosis sufferers.
All her life, Lindsay Shipp knew that she was dying. As a baby, she would cry after eating, and salt collected on her forehead. The diagnosis was cystic fibrosis, an incurable genetic disease that, at the time, meant a life expectancy of 18 years.

The disease, which affects 30,000 people in the United States, hinders the movement of salt in the body. Because of this, the pancreas fails soon after birth, patients cannot properly digest food, and their airways fill with mucus, leaving them vulnerable to lung infections and other problems. The current average life expectancy is now 37.

"The exciting thing about this is a drug that interacts directly with the defective protein and changes its function," Davis said. "Admittedly this protein is only found in about 5 percent of the patients with CF but it does appear to restore normal function."

Though more testing is needed, it might be possible to give the drug to babies to head off the disease before it begins to damage the lungs, she added.

Millions of Americans carry a defective CF gene, but do not have any symptoms. To be symptomatic, a person with CF must inherit two defective CF genes -- one from each parent. About 30,000 people have CF, according to the Cystic Fibrosis Foundation.
I had this race-against-time mentality where I did everything I could possibly do in a day," said Shipp, now 27 and working part time in San Diego as a bookkeeper and at an Apple store. "I never let a moment go to waste."

Shipp starred in her high school musicals and dreamed of auditioning on Broadway, until her lungs got so bad that she gave up singing and dancing.

But since she started taking an experimental drug as part of a closely watched clinical trial, her outlook has changed. The drug, called ivacaftor, cleared her lungs and allowed her to add a healthy 15 pounds to her 5-foot, 100-pound frame. On the day in February of last year when a regular checkup revealed her lungs were functioning at 96% — bringing her to essentially the same level as a healthy person — Shipp collapsed on a bench outside the hospital and sobbed with relief. "I realized I would have a full life at that moment," she said.

The trial results, published in Thursday's edition of the New England Journal of Medicine, showed that ivacaftor reduced the incidence of pulmonary exacerbations — sudden, serious flare-ups that can send patients to the hospital and cause irreversible lung damage — by 55% compared with a placebo. The study of 161 patients also found that patients who took the drug saw their lung function improve 10.4% and gained nearly 6 pounds over 48 weeks.

"This is exciting work," said Michael Welsh, a pulmonary physician at the University of Iowa who was not involved in the study. "I think that it is very promising for the people who have this particular mutation, and it may turn out to have broader significance."

Ivacaftor affects a genetic mutation in 4% to 5% of cystic fibrosis patients that prevents a protein called CFTR from allowing enough chloride ions to exit a certain type of cell. Chloride, when coupled with sodium to make salt, helps regulate the flow of water in the body. When that channel doesn't work, the lungs dry up and the once-protective mucus grows thick and immovable, providing an ideal breeding ground for bacteria.

This salt imbalance affects the pancreas and digestive tract, so patients are often small and malnourished. The sweat glands don't work properly either, leading to overly salty skin.

The drug helps that chloride gateway stay open, restoring the salt balance in the body. It is the first therapy that fixes the basic problem that causes the disease, not just the symptoms, said study coauthor Michael Konstan, a pediatric pulmonologist at Case Western Reserve University School of Medicine in Cleveland.

"The goal is if you would give a therapy like this before [the lungs deteriorate], you can prevent lung disease from developing," Konstan said.

The drug can't yet help the vast majority of cystic fibrosis sufferers: About 90% of them have a mutation in which the protein, once manufactured inside the cell, never even makes it to the cell surface where it is supposed to act as a chloride channel. Researchers are trying to develop drugs that would help bring that protein to the surface. Once a patient is on such a drug, ivacaftor could then pick up the process from there.

"It's creating such a sense of hope and optimism for all the cystic fibrosis patients because this approach will work," said Robert Beall, president and chief executive of the Bethesda, Md.-based Cystic Fibrosis Foundation, which has spent millions funding such research.
cystic fibrosis dating
Although therapies to fight the disease seemed to be around the corner when the CFTR gene was discovered in 1989, it took more than two decades to develop a treatment based on the genetic defect.

"This timeline suggests that much of the promise of the Human Genome Project has yet to be fulfilled and that realizing the therapeutic benefits will take persistence and determination," Dr. Pamela Davis of Case Western wrote in an editorial accompanying the study. "Society cannot allow support for research and development to be compromised in the current rush to cut the federal budget."

If all goes smoothly, ivacaftor may be approved by the Food and Drug Administration in 2012, said study lead author Bonnie Ramsey, a pediatric pulmonologist at Seattle Children's Hospital. The study was partially funded by ivacaftor's maker, Vertex Pharmaceuticals Inc. of Cambridge, Mass., which plans to market it under the name Kalydeco.
cystic fibrosis symptoms
The drug is not an absolute cure. It cannot rid the body of bacterial infections that stick around even after mucus has been cleared from the lungs. But perhaps, if given to patients that were young enough — say, newborns — it could allow them to live an essentially normal life.

As for Lindsay Shipp, who will be singing at the Cystic Fibrosis Conference in Anaheim this week — a downtempo cover of Katy Perry's "Firework" and "Thank You for the Music," from the musical "Mamma Mia!" — the girl who once gave up her dreams of Broadway now thinks she might fly to New York and audition.

Saturday, October 29, 2011

Anthrax vaccine to test children?

Anthrax vaccine to test children? It will be some time before the Government.

An advisory committee said on Friday, ethical issues need to be addressed - but if they can complete the vaccine in children be tested to ensure its safety and learning under the right circumstances, it is the dose required to terrorist attacks.

Fearing that terrorists might use potentially deadly bacteria, the Government has stockpiled vaccines. It has been widely adults, but never tested on children.

The question is whether to do the test, so doctors will know if the child's immune system to respond to the lens is not good enough, the signal protection. Children are not exposed to anthrax.

National Biodefense Science Board said Friday that an independent review committee should consider making such a test in a child's ethical problems. If this is successful, the group said that the Ministry of Health and Human Services should develop in the children's vaccine research program.

How to protect young people after the anthrax attacks, is a challenging problem, said Dr. Nicole Lurie, board members and public health preparedness and response services, assistant secretary. "Protection of children are still advocated that countries for me, the most important responsibilities, we as a nation."

The Board provides advice to the Ministry of Health and Human Services, chemical, biological and nuclear activities of the preparatory work. The 12-1 vote.

There is no deadline for the government to decide whether to go. If you do not agree, it's not clear how much time to find the funding of such research and medical centers clearance review committee will conduct a study.

Another big question is whether parents will sign their children to test the vaccine is no direct threat. It is impossible from the anthrax vaccine, but there are side effects. In adults, the shooting site pain, muscle aches, fatigue, headache, etc. is a major, and rare but serious allergic reactions have been reported.

Anthrax in several potential bioterrorism weapons and special interests, because it is in 2001, letters to the media and others, claiming five lives and sickening 17. This prompted extensive screening mail and postal facilities and government agencies for better ventilation and testing.
Doctors questioned whether children's immune systems to respond to the lens is not good enough, the signal protection. Children under the program will not be exposed to the test anthrax. The group said that due to the vaccine in the event of a bioterrorist attack using a large number of children, it is prudent to test whether the vaccine is safe management of children. The vote was 12 to 1 in favor of vaccination programs.

"We need to learn more about the safety and immunogenicity of the vaccine development as we plan to use a child in a bioterrorism attack, large quantities of vaccine," says Ruth Berkelman of Emory University, agreed with the members of the group plan.

The Board suggested the same earlier this year, the U.S. established a vaccination scheme.

He said: "The U.S. government must do anticipatable better preparation for emergencies, according to their nature, chemical, biological, radiological or nuclear attack is the unpredictable, but in some cases, can be expected, it is According to the U.S. Government has the responsibility for their plan, "the Panel that, in time. "Under such circumstances, including anthrax spores potential exposure of children, therefore, the U.S. government should conduct clinical trials to determine the appropriate dose of anthrax vaccine in children. Similarly, the MCM should be assessed several other pediatric medicine."

Anthrax vaccine adsorbed has provided nearly 2.5 million members of the military, the researchers say, in the adult vaccine safety and immunogenicity profiles familiar. However, vaccination of children is not yet tested to improve the vaccine may not be sufficient concern about the attack.

Test in the past faced legal problems. Against members of the military's anthrax vaccine requires the proceedings, a federal judge suspended the program in 2004, approved the drug in the Food and Drug Administration found during the failure. U.S. Food and Drug Administration reiterated its finding that the vaccine is safe.

Anthrax in several potential bioterrorism weapons and special interests, because it is in 2001, letters to the media and others, claiming five lives and sickening 17. Since then, he served as U.S. large stocks of vaccine, in another common attacks.

The Obama administration asked a federal panel to consider the children are vaccinated in effort to determine the efficacy of the vaccine potential. The Board provides advice and guidance, the Department of Health and Human Services related to chemical, biological and nuclear accident emergency preparedness and other issues. Founded in 2006, by statute, NBSB has extensive expertise in science, medicine and public health 13 voting members.
The main panel of a government adviser (Friday) suggested that the federal government sponsored a controversial study to test whether children's anthrax vaccination will prevent bio-terrorist attacks of young Americans.

National Biodefense Science Board, the federal government on bioterrorism issues, investment and 12-1 suggest, the Ministry of Health and Human Services of a study to determine whether the vaccine is safe and effective for children, and determine the best dose. Iowa Department of Public Health, who chaired the panel, Quinlisk Patricia is the only opponents.

"We need to learn more about vaccine safety and immunogenicity, as we plan to use a large number of bio-terrorist attacks of childhood vaccines, said:" Lucy Siaimoli University, a team member Berkelman.

Panel adopted the recommendations of Berkelman, after further review of another group to specialize in difficult ethical issues it raises.

Assistant Secretary of HHS preparedness and response requires the Panel to review, Nicole Lurie, said officials will consider the Panel's recommendations, but she did not give a time frame of the decision.

Although the overwhelming majority of the panel to conduct a study, several critics said that this test is immoral, unnecessary risk.

"Vera said:" The open trial of major damage to children's health not good possibilities for human research protection advocacy group in New York League of Sharav.

Anthrax is a bacterial toxin produced by a life-threatening infections. It has long been considered possible options for bioterrorism, because it is relatively easy, large-scale production and distribution.

The federal government has spent $ 1.1 billion in reserves of vaccines to protect the American attacks. Although antibiotics will help to protect those immediately exposed, the vaccine to protect against lingering spores.

In 1998, the Pentagon began a controversial vaccination program, vaccine safety and reliability problems, which is challenged in court by military personnel.

The vaccine has been extensively tested in adults and more than 260 million people in the military administration. But the shot has never been tested or to their children, leaving it uncertain how the young people and in what doses of vaccine, and it is safe.

FBI accused of Bruce Ivins, the Army biodefense lab scientist, committed suicide before he could receive mail attacks.

Anthrax can be difficult to treat, especially if someone inhaled anthrax spores. Saved millions of doses of antibiotics since 2001 episode, two experimental treatments are being clear of toxins stored.

U.S. troops deployed to Iraq, Afghanistan and other countries need to be anthrax shot. Since 1998, more than 100 million have been vaccinated. Against the requirements of the proceedings, a federal judge suspended the program in 2004, approved the drug in the Food and Drug Administration found during the failure. Next year, the U.S. FDA reaffirmed its finding that the vaccine is safe.

Role of diet in breast cancer?

Since October is Breast Cancer Awareness Month, this is a perfect time to answer this question.

The answer is yes. To give you the best information, I turned to a registered dietitian Sally Sike Luo Rodriguez, MS, RD, LD, and Clare McKinley, RD, LD, at the University of Texas MD Anderson Cancer Center, the world's leading cancer hospitals. They explained that the risk of breast cancer can be reduced to 38% by lifestyle factors, including maintaining a healthy weight, regular exercise, healthy diet. In fact, there is less than 10% of breast cancer have a genetic basis.

For breast cancer prevention, restriction of alcohol a day, drink (wine 5 ounces, 12 ounces of beer, or 1.5 oz liquor) is the most important thing you can do one. In addition, plant-based diet with a variety of agricultural products, at least two cups a day is beneficial.

According to the American Association for Cancer Research ", no single food or food ingredient can prevent cancer itself, but scientists believe that the main food plant-based diet in combination, there is evidence that, minerals, vitamins and plant foods of plant chemicals can interact to enhance their personal role in cancer. This concept of interaction, of which 1 + 1 = 3, is called synergy. "

Choice of some cancer prevention, including beans, berries, cruciferous vegetables (broccoli, cauliflower, cabbage, Brussels sprouts), dark leafy green vegetables (spinach, cabbage, beets, lettuce, mustard), flax, garlic, grapes / grape juice, green tea, soy, tomatoes and whole grains. A recent study in mice shows that walnuts can also play a role in the prevention of breast cancer, but these findings need confirmation in humans.

There is also a growing number of studies have shown that the body, one of the active ingredient in curry, curcumin may play a role in the treatment and prevention of various cancers, including breast cancer.

Overweight postmenopausal breast cancer risk is closely linked. 22-44 lbs adult weight gain and a greater risk and 50% of body weight by 45 pounds, and 87% increased risk.

Excess abdominal fat seems to be particularly harmful, most likely because of inflammation and its association with insulin levels, so if you tend to be more "apple-shaped" and carry extra weight, in your abdomen, which is especially important to lose weight, exercise regularly, and limit refined grains, sugar, sweet drinks, and add sugar to your diet.

When it comes to breast cancer survivors and healthy lifestyle is equally important, if not more. Many women are concerned about soy consumption, I wrote about before. Sally and Claire agree to up to three a day is safe, but they stressed, should be from whole soy foods such as soy milk, soybeans and tofu, like smoothies, bars, fortified cereals and soybeans to supplement should be limited.
The women taking multivitamins longer life than those who do not take the pill, may actually die sooner, a large new study found.

Involving about 39,000 women, aged between 55 and 69 when the study began, 19 years of follow-up study.

During this period, approximately 40% of deaths. When the researchers looked at who the vitamins, multivitamins than those who choose not to add a slightly higher risk of death. The same women regularly participate in iron, vitamin B6, folic acid, magnesium, zinc, copper.

In fact, the researchers observed a 15 to add, only calcium and a lower risk of death.

While in Archives of Internal Medicine, research, do not look at men's authors say their results are likely to expect the same for them.

The study found that vitamins and increased risk of death between the link; it does not prove that the supplement caused the death. The authors say their findings underlying cause is not clear.

"We see an overall increase in mortality risk, but we really do not know why," lead author Jaakko Mursu, University of Eastern Finland and the University of Minnesota, told CTV News.

But they noted that the study adds to a growing body of research shows that vitamin may help prevent disease, and may, in fact, may increase the risk of death emerged in recent years.

But vitamins are still very popular, even if a little difficult to study, there are some add.

Commenting on the research side, the University of Nis in Serbia, the University of Copenhagen, Denmark, and Dr. Christian Gluud said Dr. Golan Bjelakovic, many people continue to have the misconception that if a little vitamin is good, then we will be better.

"Until recently, the adverse effects of dietary supplements has been limited data, grossly underestimated, we believe that paradigm," the more the better "is wrong," they wrote.

"We can not recommend the use of vitamin and mineral supplements as a precautionary measure, at least not a well-nourished population," they conclude.

However, they added, older women, maybe men might benefit from vitamin D supplements, especially if they have enough vitamin D from their diet and sun exposure. As for calcium, "may require further research," they added.

For the study, Mursu led the research team from the Iowa Women's Health Study to analyze the data. In this study, in 1986, a 16-page questionnaire filled, their diet, their use of vitamins and their general health of women. They recorded their use of multivitamins, vitamin A, C, D and E and β-carotene, B vitamins and minerals such as calcium, copper, magnesium, selenium and zinc.

They were asked in 1997 and 2004, the complementary use them again. During the study period, from 62.7% in 1986 to 85.1% in 2004, the women said they participated in one or more vitamin ratio soared.

The researchers found that a variety of vitamin users account for 41% mortality over 19 years of follow-up compared to 40% of non-users.

The problem is particularly acute take iron: women more iron, the higher their risk of death.

Only calcium and a lower risk of death, and died 37% of users compared to 43% of non-users.

The researchers pointed out that previous studies have shown that vitamin users generally tend to have a healthy lifestyle. But they also said it is possible that some women took vitamin remedies, may affect their risk of death of the health problem or disease.
Finally, in the course of treatment, diet is very important to maintain optimal health and energy level, but before taking any supplement, best to consult a registered dietitian, preferably one with experience in cancer treatment, because of some additional, may actually interfere with chemotherapy or radiation.

In general, the focus should be on the whole food rich in antioxidants. Vitamin C may need to add, in some cases, if there is not enough food consumption. To find a Registered Dietitian, American Dietetic Association's website.

I hope your facts, you can make your breast cancer risk, is encouraged by lifestyle differences. Fighting breast cancer following a few recipes from the MD Anderson get you started in the right direction. A study reveals that women who have a diet consisting of meat and a variety of livestock products like milk, eggs and dairy products may reduce the risk of breast cancer. As for those who receive much intake of foods high in fiber like fruits, vegetables and grains, show a low risk of ovarian cancer. In the research team, Dr. Endofi check diet 3600 women who had breast and ovarian cancer which is then compared with 413 healthy women. Finally, the team found four groups of eating.

One group of adherents of the pattern of ‘animal protein’ that is eating red meat in large amounts of saturated fat, zinc, calcium and a number of other nutritious meal. Second is the group to have a diet rich in vitamins and fiber, beta carotene and other nutrients found in fruits and vegetables. The third group with unsaturated fat diet, which contains a high content of vegetable oils and fish oil, in addition to vitamin E. The four groups with diets high carbohydrate content of vegetable protein and sodfium. Of the four groups, the researchers found those who consumed the diet rich in vitamins and rich in fiber is the group with ovarian cancer risk is low.

The adherents of the unsaturated fat diet have a lower risk of breast cancer, and those who ate foods with high carbohydrate have a risk of both cancers.

Health insurer Cigna's profit

CIGNA Corporation, said Friday its third-quarter profit fell 35 percent, as some companies discontinued years ago, managed care companies more hits.

Bloomfield, Connecticut, health insurance company, its net income fell to $ 2 million, or 74 cents a share, as of September 30, three months from a year ago, 307 million, or each shares of $ 1.13, $.

Adjusted gross income per share $ 1.20. Accept the average estimate of analysts polled by FactSet, earnings per share $ 1.23.

Income from a year ago of $ 5.27 billion USD, 5.61 billion U.S. dollars by nearly 7%. Analysts expected revenue of $ NR, billion.

Cigna said the results included in the profit and loss, its guaranteed minimum income benefits and variable annuity death benefits business for a total of $ 1,790,000, or 66 cents per share,. Loss was mainly due to low interest rates and "continuing volatile equity market conditions." In contrast, the total loss, compared with $ 44 million, or 16 cents per share.

In 2000, CIGNA stopped running these companies and their mode, which means that its purpose is not new business. But they can still hurt the company's performance, when the market turns bad, because of their CIGNA's liabilities.

Insurance companies said that in the field of health care, its largest business, members rose slightly to about 11.5 million people.
CIGNA's third-quarter profit fell 35 percent, as companies cut more from some of the hit, but the main part of the revenue growth and has become the latest managed care company forecast 2012 growth.
CIGNA is the fourth largest commercial health insurer based on enrollment. It is operating in the U.S. health care, group disability and life areas, the insurer also has an international division in several countries, sales and operation of personal insurance covers people living outside their home countries of foreign business.

Cigna said earlier this week that it expects 2011 adjusted profit of $ 5.05 to $ 5.30 per share, which is from the previous 4.95 to 5.25 U.S. dollars forecast. Analysts expected $ 5.29 per share annual profit. Bloomfield, Connecticut, health insurance company on Friday said it expects its healthcare members next year to add at least 40 million people.

Chief Executive Officer David Cordani told analysts revenue and earnings per share will grow to 2012, excluding discontinued business or its recently announced $ 380 million acquisition of HealthSpring's CIGNA did not affect earnings in 2012 to provide for the specific Forecast.

Health insurance companies have begun to analysts expect them to report third quarter of next year's number sense, WellPoint company also said it expects earnings growth. Another insurance company, Aetna Inc. said Thursday it expects to at least 2012 to 2012 net income per share $ 4.80, but the company believes that its profit potential on the floor.

The department heads to the 2011 health care reform to a new rule of the uncertainty of the medical loss ratio - in essence, the insurer takes care of the percentage of premiums - will affect their business. The impact of the rule turned out to be easy to manage, the company is moving in 2012 with continued growth in use of health care at a lower interest rate than they expected, which helps their performances.

Aetna Chief Financial Officer Joe Zubretsky said: "We are the prospects for progress here, we are very optimistic," Thursday after his company reported better-than-expected third-quarter 2011 revenue and improve its profit forecast.

CIGNA said Friday its net income fell to $ 2 million, or 74 cents a share, 307 million, or $ 1.13 per share, a year ago, in three months, ended September 30, on.

Adjusted earnings, excluding discontinued one of its loss per share of $ 1.20. Accept the average estimate of analysts polled by FactSet, earnings per share $ 1.23.

Income from a year ago of $ 5.27 billion USD, 5.61 billion U.S. dollars by nearly 7%. Analysts expected revenue of $ NR, billion.

Company's shares fell 14 cents to close at $ 46.63 (Friday).

CIGNA said Friday its third-quarter results included a total loss of 179 million, or 66 cents per share, from the guaranteed minimum income benefits and variable annuity death benefits business, due to low interest rates and stock market volatility. In contrast, the total loss, compared with $ 44 million, or 16 cents per share.

In 2000, CIGNA stopped running these companies and their mode, which means that its purpose is not new business. But they still hurt the company's performance, when the market turns bad, because of their CIGNA's liabilities.

CIGNA is the fourth largest commercial health insurer based on enrollment. It is operating in the U.S. health care, group disability and life areas, the insurer also has an international division in several countries, sales and operation of personal insurance covers people living outside their home countries of foreign business.

The largest segment of the market, health care, insurance premiums and costs fell 3% to $ 3.3 billion, and medical membership rose slightly to about 11.5 million people.

The insurer has said that its international business is an important future source of economic growth. Premiums from the business and expenses increased 33%, to $ 765 million in the quarter.

Cigna also said earlier this week that it expects 2011 adjusted profit of $ 5.05 to $ 5.30 per share, which is from the previous 4.95 to 5.25 U.S. dollars forecast. Analysts expected $ 5.29 per share annual profit.